Loading clinical trials...
Loading clinical trials...
Safety & Efficacy of Prolonged Physiologic Erythropoietin (EPO) Level Treatment of Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)Using MDGN201 TARGTEPO
Conditions
Interventions
MDGN201 TARGTEPO
Locations
2
Israel
Barzili Medical Center
Ashkelon, Israel
Assaf Harofeh Medical Center
Zrifin, Israel
Start Date
April 1, 2015
Primary Completion Date
January 1, 2016
Completion Date
June 1, 2016
Last Updated
October 19, 2018
Lead Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions